Metropolis Healthcare

Crisil revises Metropolis outlook to positive, reaffirms 'AA-' rating

Crisil Ratings has revised its outlook on the long-term bank facilities and non-convertible debentures of Metropolis Healthcare Ltd (MHL) to 'positive' from 'stable', while reaffirming its rating at 'Crisil AA-'. The rating agency also reaffirmed its short-term bank facility rating at 'Crisil A1+', according to a note from Crisil Ratings. Crisil said the outlook revision reflects the expected improvement in organic revenue growth, profitability, and cash accruals, along with a meaningful turnaround in its recent acquisition, Core Diagnostics Pvt Ltd. Higher utilisation of the expanded laboratory network, a favourable test mix, and better profitability at Core Diagnostics are expected to support healthy operating margins over the medium term, the agency noted. According to the rating agency, MHL's revenue increased 24 per cent to Rs 1,646 crore in FY26, driven by higher patient volumes and specialised diagnostic and wellness tests under the 'TruHealth' brand. Revenue growth continu

Robust demand, pricing to keep volumes strong for diagnostics sector

Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage

Metropolis eyes Rs 2,500-cr-plus revenue in 3 years; M&A could add upside

Diagnostics chain plans to sweat existing lab infrastructure, expand company-owned centres from 750 to 1,000

Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%

Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.

Dividend, bonus, rights issue: Keep an eye on these 4 stocks next week

Investors will keep an eye on DIC India, as the company has declared a final dividend of ₹3 per share, with the record date fixed on March 16

Next phase of growth is about improving utilisation: Surendran Chemmenkotil

In a video-interview with Sohini Das, Surendran Chemmenkotil, Managing Director of Metropolis Healthcare, speaks about the company's FY27 network expansion strategy

Metropolis Q3FY26 results: Profit jumps 32%, revenue rises nearly 26%

India's second-largest pathology chain reported strong year-on-year profit growth in the December quarter, supported by higher test volumes, preventive care demand and specialised diagnostics

Metropolis Healthcare shares jump 6% on 26% revenue growth in Q3 update

Metropolis Healthcare shares rose 6 per cent it reported a 26 per cent Y-o-Y jump in its standalone revenue in the third quarter of the current financial year

Metropolis launches GLP-1 monitoring test packages, targets obesity market

Metropolis Healthcare has rolled out three TruHealth GLP-1 test packages for patients preparing for or undergoing obesity treatment, as diagnostics firms move to tap the fast-growing segment

Metropolis Q2 results: Profit up 13% on higher patient, test volumes

Metropolis Healthcare posted a 13% rise in Q2FY26 net profit to ₹53 crore, driven by increased patient and test volumes, network expansion, and improved performance across regions

Will Apollo, Max, Metropolis outshine peers in Q2? Here's what analysts say

Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.

Metropolis Healthcare rises 4% on releasing Q2 update; check details

According to the company filing, it delivered a 23 per cent year-on-year (Y-o-Y) revenue growth at the consolidated level, driven by robust momentum in preventive health check-ups

Metropolis Healthcare acquires Kolhapur-based pathlab chain for ₹17 crore

Metropolis added that the move is expected to enhance productivity and drive overall profitability across its network of laboratories operating in the region

Dixon, Metropolis, 2 other stocks flag Buy signal, can rally up to 34%

Technical charts show that Dixon Technologies, Kirloskar Oil Engines, Metropolis Healthcare and RHI Magnesita have witnessed a 'Golden Crossover', hence are likely to see upside in the near-term.

Metropolis Healthcare unperturbed by Amazon's diagnostics segment foray

'Amazon's entry is through a partnership with Orange Health. It is more of a distribution through Amazon'

These 2 midcap, 3 smallcap stocks trade in overbought zone; strategy here

Despite trading in overbought territory Delhivery, Metropolis Health look poised for up to 19% further gains, while Usha Martin stock could dip 9%; suggest technical charts.

Stocks to watch today, May 14: Tata Motors, HAL, Eicher, Lupin, Airtel

At 6:40 AM, GIFT Nifty futures were trading 90 points higher at 24,730 level, indicating a higher start.

Metropolis Healthcare Q4 results: Net profit falls 19.9%, revenue up 4.3%

Metropolis Q4 profit dips due to one-off costs from acquisitions; FY25 profit rises 13.4% on demand for preventive testing and strong B2C, B2B growth

Metropolis Healthcare expands footprint in North with Dapic acquisition

With its third acquisition in recent times, Metropolis' Ameera Shah said the firm will make another deal this financial year

Metropolis Healthcare to acquire DAPIC for ₹35 crore in all-cash deal

Under the agreement, Metropolis' wholly-owned subsidiary Metropolis Histoxpert Digital Services Pvt Ltd will acquire 100 per cent ownership of DAPIC